Inhalation Anesthesia

Inhalation Anesthesia Market Outlook

The global inhalation anesthesia market is projected to reach approximately USD 2.3 billion by 2035, expanding at a CAGR of around 5.4% during the forecast period from 2025 to 2035. The growth of this market is primarily driven by the rising number of surgical procedures worldwide, increased prevalence of chronic diseases requiring surgical interventions, and advancements in anesthetic technologies that enhance patient safety and recovery times. Additionally, the increasing number of ambulatory surgical centers and the growing awareness of the availability and benefits of inhalation anesthesia are further contributing to market expansion. Furthermore, the ongoing research and development efforts aimed at improving anesthetic formulations and delivery methods are expected to fuel market growth.

Growth Factor of the Market

One of the key growth factors for the inhalation anesthesia market is the rising incidence of surgeries globally, driven by factors such as the aging population, lifestyle changes, and the increased prevalence of conditions such as obesity and cardiovascular diseases. As hospitals and surgical centers seek to improve patient outcomes and reduce complications, the demand for efficient and effective anesthetic agents becomes paramount. Additionally, advancements in anesthetic delivery systems, such as precision vaporizer technology and monitoring systems, are boosting the uptake of inhalation anesthesia, making procedures safer and more reliable. The growing trend towards outpatient surgeries, which require short-acting anesthetics, is also propelling market growth. Moreover, the shift towards minimally invasive surgical techniques, which often necessitate the use of inhalation anesthesia, is further expected to contribute positively to market dynamics.

Key Highlights of the Market

• The inhalation anesthesia market is anticipated to witness a robust CAGR of 5.4% from 2025 to 2035.
• Sevoflurane is expected to dominate the product type segment based on its widespread use and favorable pharmacokinetic properties.
• Hospitals are projected to hold the largest share of the application segment due to the high volume of surgical procedures performed.
• Online pharmacies are emerging as a significant distribution channel, driven by the growing trend of e-commerce and telehealth services.
• North America is expected to maintain its leading position in the inhalation anesthesia market due to advanced healthcare infrastructure and high surgical volumes.

By Product Type

Sevoflurane:

Sevoflurane is a widely used inhalation anesthetic known for its rapid onset and offset properties, making it particularly suitable for outpatient procedures. It is favored in both pediatric and adult surgeries due to its minimal irritation to the airway and favorable hemodynamic stability. Sevoflurane's low blood-gas partition coefficient leads to quicker recovery times, which enhances patient satisfaction and operational efficiency in surgical settings. As a result, it continues to gain traction in hospitals and ambulatory surgical centers, establishing itself as a preferred choice among anesthesiologists. The increasing preference for sevoflurane in various surgical specialties is anticipated to drive its market growth significantly.

Desflurane:

Desflurane is another prominent inhalation anesthetic known for its rapid elimination from the body, allowing for quick recovery from anesthesia. Its low blood-gas solubility enables fast induction and recovery, making it an ideal choice for ambulatory surgeries where patients can be discharged shortly after the procedure. Desflurane is often used in surgeries that require short anesthetic durations, as its pharmacokinetic profile supports quick transitions between sedation and recovery. However, its higher cost compared to other agents may limit its use in some settings, but its advantages in specific surgical applications continue to drive demand.

Isoflurane:

Isoflurane is a well-established inhalation anesthetic agent characterized by its efficacy and relatively low cost. It is commonly used in various surgical procedures due to its potent anesthetic properties and ease of use. Isoflurane has been utilized extensively in both human and veterinary medicine, contributing to its robust market presence. While it may not be as favored as sevoflurane or desflurane for outpatient procedures due to slower recovery times, it remains a reliable choice in many hospital settings. Its demonstrated effectiveness and widespread acceptance in the medical community are expected to maintain its relevance in the inhalation anesthesia market.

Nitrous Oxide:

Nitrous oxide, often referred to as "laughing gas," is primarily used as an adjunct to other anesthetics due to its analgesic properties and mild sedative effects. It is commonly employed in dental procedures and minor surgeries, where it provides rapid onset of anesthesia and quick recovery. Nitrous oxide is particularly appealing in outpatient settings because it does not require extended monitoring after administration. Its ability to enhance the effects of other anesthetics while minimizing risks makes it a valuable component of inhalation anesthesia protocols. The growing application of nitrous oxide in a range of medical procedures is anticipated to support its ongoing demand in the market.

Halothane:

Halothane is an inhalation anesthetic that has been used for decades, known for its effectiveness in inducing general anesthesia. However, its use has declined in recent years due to concerns over potential side effects such as hepatotoxicity and cardiovascular complications. While halothane is less favored compared to newer agents, it remains in use in some regions and specific medical applications. Its historical significance in anesthesia and the ongoing utilization in certain clinical scenarios contribute to its continued presence in the inhalation anesthesia market, albeit at a reduced scale.

By Application

Hospitals:

Hospitals represent the largest application segment for inhalation anesthesia, driven by the high volume of surgical procedures performed across various specialties, including general surgery, orthopedics, and cardiovascular surgery. The presence of advanced surgical infrastructure, skilled anesthesiology teams, and comprehensive perioperative care makes hospitals the primary setting for inhalation anesthesia administration. The increasing complexity of surgeries and the necessity for efficient anesthetic management in high-risk patients further bolster the demand for inhalation anesthetics in hospital settings. As surgical volumes continue to rise, the hospital application segment is expected to maintain its dominant market share over the forecast period.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are gaining prominence due to the growing trend toward outpatient surgeries, where patients can undergo procedures and return home on the same day. Inhalation anesthesia is favored in these settings due to its rapid onset and recovery profiles, which align with the operational requirements of ASCs. The increasing acceptance of minimally invasive techniques and advancements in anesthetic technologies are contributing to the rise of ASCs as viable alternatives to traditional hospital settings. The convenience, cost-effectiveness, and patient-centered approach of ASCs are expected to drive the demand for inhalation anesthesia within this application segment significantly.

Clinics:

Clinics, particularly those specializing in dental and minor surgical procedures, constitute a notable application segment for inhalation anesthesia. In these settings, anesthetic agents such as nitrous oxide are commonly used to provide sedation and anxiety relief for patients undergoing procedures. The growing number of clinics offering outpatient services further supports the demand for inhalation anesthetics. The use of inhalation anesthesia in clinics is bolstered by its advantages in terms of patient comfort, reduced recovery times, and improved procedural outcomes. As the number of clinics offering surgical and dental services continues to grow, the inhalation anesthesia market within this segment is anticipated to expand.

Others:

Other applications for inhalation anesthesia include specialized medical settings, such as veterinary practices and research institutions. In veterinary medicine, inhalation anesthetics are utilized for surgical procedures on animals, with a focus on ensuring their safety and comfort during anesthesia. Additionally, research institutions may employ inhalation anesthesia in experimental procedures or studies involving anesthesia-related research. While these applications represent a smaller portion of the overall market, they are important segments that contribute to the diversity of inhalation anesthesia use. The growth of veterinary services and research initiatives is expected to sustain demand in these niche areas.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as a primary distribution channel for inhalation anesthesia, catering to the extensive needs of surgical departments and operating rooms. These pharmacies ensure the availability of a wide range of anesthetic agents to meet the demands of various surgical procedures. The established relationships between hospitals and pharmaceutical manufacturers facilitate efficient procurement and distribution processes. Hospital pharmacies play a critical role in managing inventory, ensuring compliance with regulations, and providing the necessary support for anesthesiology teams. With the increasing number of surgical cases, the demand for inhalation anesthesia through hospital pharmacies is expected to grow steadily.

Retail Pharmacies:

Retail pharmacies are emerging as an important distribution channel for inhalation anesthesia, particularly for outpatient procedures and home healthcare applications. The growing trend towards self-administered anesthesia, especially in dental and minor surgical procedures, is driving the demand for anesthetic agents available through retail outlets. Retail pharmacies often offer a range of anesthetic products, ensuring patients have access to inhalation anesthesia when needed. As consumer awareness regarding the availability and benefits of these products increases, the market share of retail pharmacies is anticipated to rise, contributing positively to the overall inhalation anesthesia market.

Online Pharmacies:

Online pharmacies are revolutionizing the distribution of inhalation anesthesia by providing convenient access to anesthetic agents for both healthcare providers and patients. The digitalization of pharmacy services allows for easy ordering and delivery, which is particularly beneficial for outpatient care settings. The growing acceptance of telehealth services and the trend towards e-commerce are driving the expansion of online pharmacies in the medical field. With the added benefits of competitive pricing and promotional offers, online pharmacies are likely to capture a significant share of the inhalation anesthesia market, catering to the evolving needs of patients and healthcare providers alike.

Others:

Other distribution channels for inhalation anesthesia may include specialty medical suppliers and wholesalers that cater to specific healthcare facilities, such as long-term care institutions and surgical centers not affiliated with hospitals. These channels often focus on providing customized solutions and tailored services to meet the unique inventory and anesthetic needs of various institutions. While these channels represent a smaller segment of the overall distribution landscape, they play a crucial role in ensuring that inhalation anesthesia products are readily available where they are needed. The diversification of distribution channels is expected to enhance overall market access and availability of inhalation anesthetics.

By Ingredient Type

Oxygen:

Oxygen is a critical component in inhalation anesthesia, often used in combination with other anesthetic agents to ensure patient safety and effective sedation. It is essential for maintaining adequate oxygenation during anesthesia, particularly in patients with compromised respiratory function or those undergoing lengthy surgical procedures. The demand for oxygen in inhalation anesthesia is driven by its necessity in delivering safe and effective anesthesia, as well as advancements in oxygen delivery systems that enhance patient outcomes. This growing reliance on oxygen as a fundamental ingredient in anesthesia protocols is expected to bolster its market share in the inhalation anesthesia sector.

Nitrous Oxide:

Nitrous oxide serves as an important ingredient in inhalation anesthesia due to its analgesic and sedative properties. Frequently used in dental procedures and outpatient surgeries, nitrous oxide allows for rapid onset and recovery, making it a popular choice among healthcare providers. Its ability to enhance the effects of other anesthetic agents while minimizing risks further supports its ongoing demand in the market. The increasing awareness of nitrous oxide's benefits and its incorporation into various anesthesia protocols are likely to solidify its position as a key ingredient in the inhalation anesthesia market.

Xenon:

Xenon is an emerging anesthetic agent that has garnered attention due to its unique properties, including rapid onset, minimal side effects, and neuroprotective effects. Although its use remains limited compared to more established agents, xenon is being researched for its potential applications in anesthesia, particularly in high-risk patients and complex surgeries. The growing interest in xenon as a novel anesthetic option may lead to its increased adoption in the coming years, contributing to the diversification of ingredients used in inhalation anesthesia protocols. Ongoing studies aiming to elucidate its benefits and safety profile will be critical in determining its future market presence.

Helium:

Helium is a less common ingredient in inhalation anesthesia but has been explored for its potential applications in certain medical scenarios. Its low density and inert properties make it an interesting candidate for use in combination with other anesthetic agents, particularly in specific clinical settings. Research into the effects of helium on respiratory function and anesthetic efficacy may pave the way for its application in specialized anesthesia protocols. As the medical community continues to explore innovative approaches to anesthesia, helium may find its niche within the inhalation anesthesia market, particularly as part of multi-component anesthetic strategies.

By Region

The inhalation anesthesia market is poised for significant growth across various regions, with North America leading the charge due to its advanced healthcare infrastructure and high surgical volumes. The North American market is projected to witness a CAGR of approximately 5.8% from 2025 to 2035, driven by the increasing prevalence of chronic conditions that necessitate surgical interventions and the adoption of advanced anesthetic technologies. The presence of key pharmaceutical manufacturers and robust healthcare policies further bolster market growth in this region, making it a focal point for inhalation anesthesia innovations and practices. Hospitals, ambulatory surgical centers, and clinics in North America are expected to contribute significantly to the overall demand for inhalation anesthetics.

Europe is another vital region in the inhalation anesthesia market, characterized by a well-established healthcare system and a growing number of surgical procedures performed annually. The European market benefits from a high level of awareness regarding new anesthetic agents and technologies, which promotes the adoption of safer and more effective inhalation anesthesia practices. Additionally, the increasing focus on outpatient surgeries within European healthcare systems aligns with the need for rapid recovery anesthetics, thereby driving demand for inhalation anesthetics. Other regions, including Asia Pacific and Latin America, are also witnessing growth, driven by rising surgical volumes and improving healthcare access, but the overall market share remains lower than that of North America and Europe.

Opportunities

The inhalation anesthesia market presents numerous opportunities for expansion and innovation, particularly as the healthcare landscape continues to evolve. One significant opportunity lies in the increasing adoption of outpatient surgical procedures, which require anesthetics with rapid onset and shorter recovery profiles. As more patients seek minimally invasive options that allow for same-day discharge, the demand for inhalation anesthetics that meet these criteria is expected to rise. Additionally, advancements in anesthetic delivery systems, such as precision vaporizer technology and enhanced monitoring capabilities, will further drive the need for innovative inhalation anesthetics. This shift toward outpatient care is likely to open new avenues for growth and development within the inhalation anesthesia market, as healthcare providers prioritize patient safety and satisfaction.

Moreover, the rise of telemedicine and digital health platforms creates opportunities for enhancing patient access to inhalation anesthesia resources. As telehealth services become more integrated into surgical practices, anesthesiologists can leverage digital tools to optimize preoperative consultations, patient education, and postoperative follow-ups. The development of educational resources and teleconsultation services focused on inhalation anesthesia can help patients understand their options, ease anxiety, and improve overall surgical experiences. Furthermore, the global push for health equity and access to quality care presents opportunities for inhalation anesthesia manufacturers to expand into underserved markets, making effective anesthetic solutions available to a broader demographic of patients.

Threats

Despite the promising growth prospects, the inhalation anesthesia market faces several threats that could hinder its development. One major challenge is the increasing scrutiny surrounding the safety and potential side effects of inhalation anesthetics. Regulatory agencies and healthcare professionals are becoming more vigilant regarding the long-term effects of anesthetic exposure, particularly in vulnerable populations such as pediatric and geriatric patients. This heightened awareness may lead to stricter regulations and guidelines, potentially limiting the use of certain inhalation anesthetics or impacting their market dynamics. Additionally, the emergence of alternative anesthetic techniques, such as regional anesthesia and intravenous sedation, poses a competitive threat to inhalation anesthesia, as healthcare providers explore safer and more effective options for pain management and sedation.

Another significant threat to the inhalation anesthesia market is the potential for supply chain disruptions, especially in light of recent global events such as the COVID-19 pandemic. The reliance on specific suppliers for anesthetic agents and related equipment means that any disruptions in production or distribution can directly impact availability in healthcare settings. Manufacturers may face challenges in maintaining consistent supply levels, leading to increased costs and potential shortages of critical anesthetic products. Additionally, geopolitical tensions and trade restrictions could further complicate the supply chain for inhalation anesthesia products, making it imperative for manufacturers to diversify their sourcing strategies and develop contingency plans to mitigate risks.

Competitor Outlook

• AbbVie Inc.
• Halocarbon Products Corporation
• Fresenius Kabi AG
• Halyard Health, Inc.
• Meda Pharmaceuticals
• Philips Healthcare
• Drägerwerk AG
• GE Healthcare
• Merck & Co., Inc.
• Smiths Medical
• Abbott Laboratories
• MSD (Merck Sharp & Dohme)
• Piramal Enterprises Ltd.
• Baxter International Inc.
• Vyaire Medical Inc.

The inhalation anesthesia market is characterized by a competitive landscape featuring several key players striving to maintain their market positions through innovation and strategic initiatives. Major companies such as AbbVie Inc. and Fresenius Kabi AG are focusing on expanding their product portfolios and enhancing their anesthetic formulations to address the evolving needs of healthcare providers. These companies invest significantly in research and development efforts to bring forth new inhalation anesthetics and delivery systems that prioritize patient safety and efficacy. Collaborations with hospitals and surgical centers further amplify their market presence, allowing them to establish strong relationships and ensure a steady supply of anesthetic agents to meet growing demand.

Drägerwerk AG and GE Healthcare are also prominent players in the inhalation anesthesia market, concentrating on advanced anesthetic delivery systems and monitoring technologies. Their commitment to innovation has led to the development of cutting-edge vaporizer systems and patient monitoring solutions that enhance the overall anesthesia experience. By integrating technology with traditional anesthetic practices, these companies are not only improving patient outcomes but also positioning themselves as leaders in the anesthesia space. The continuous pursuit of excellence in product development and operational efficiency will enable these companies to capitalize on emerging market opportunities while staying ahead of the competition.

The competitive dynamics of the inhalation anesthesia market are further influenced by a number of smaller and niche players, such as Halyard Health, Inc. and Piramal Enterprises Ltd., who offer specialized anesthetic products and services tailored to specific applications. These players often focus on regional markets or specific clinical needs, providing unique solutions that cater to healthcare providers looking for alternatives to mainstream anesthetic agents. As the market landscape becomes increasingly diverse, these smaller companies play an essential role in driving innovation and fostering competition within the inhalation anesthesia sector. Overall, the interplay between these major players and niche competitors will shape the future trajectory of the inhalation anesthesia market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 AbbVie Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 GE Healthcare
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Smiths Medical
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Fresenius Kabi AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Merck & Co., Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Philips Healthcare
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Vyaire Medical Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Drägerwerk AG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Halyard Health, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Meda Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Piramal Enterprises Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Baxter International Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 MSD (Merck Sharp & Dohme)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Halocarbon Products Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Inhalation Anesthesia Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Ambulatory Surgical Centers
    • 6.1.3 Clinics
    • 6.1.4 Others
  • 6.2 Inhalation Anesthesia Market, By Product Type
    • 6.2.1 Sevoflurane
    • 6.2.2 Desflurane
    • 6.2.3 Isoflurane
    • 6.2.4 Nitrous Oxide
    • 6.2.5 Halothane
  • 6.3 Inhalation Anesthesia Market, By Ingredient Type
    • 6.3.1 Oxygen
    • 6.3.2 Nitrous Oxide
    • 6.3.3 Xenon
    • 6.3.4 Helium
  • 6.4 Inhalation Anesthesia Market, By Distribution Channel
    • 6.4.1 Hospitals Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Inhalation Anesthesia Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Inhalation Anesthesia market is categorized based on

By Product Type

• Sevoflurane
• Desflurane
• Isoflurane
• Nitrous Oxide
• Halothane

By Application

• Hospitals
• Ambulatory Surgical Centers
• Clinics
• Others

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Oxygen
• Nitrous Oxide
• Xenon
• Helium

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• AbbVie Inc.
• Halocarbon Products Corporation
• Fresenius Kabi AG
• Halyard Health, Inc.
• Meda Pharmaceuticals
• Philips Healthcare
• Drägerwerk AG
• GE Healthcare
• Merck & Co., Inc.
• Smiths Medical
• Abbott Laboratories
• MSD (Merck Sharp & Dohme)
• Piramal Enterprises Ltd.
• Baxter International Inc.
• Vyaire Medical Inc.